Solid Lesions of the GI Tract or of Adjacent Organs
Conditions
Keywords
EUS-FNA, Forward viewing EUS scope, Curvilinear EUS scope
Brief summary
The intent of this study is to compare the performance of the CLA-EUS versus the FV-EUS in the performance of EUS-FNA of patients with solid lesions of the GI tract and of adjacent organs, with the aim of establishing for which lesions and from which location the capability of the FV-EUS will be superior, equal or, inferior to the CLA-EUS
Detailed description
Recently, a forward viewing linear echoendoscope (FV-EUS) has been developed with the aim of potentially expanding the therapeutic applications of EUS. This prototype is a modification of the CLA scope and it is characterized primarily by a shifting of the orientation of the endoscopic and US views from oblique to forward. The US transducer is located adjacent to the working channel, at the endoscope tip, to display a forward-viewing image along to a scanning plane that is parallel to the insertion direction with a 90° scanning range. It has a 3.7 mm working channel without elevator, which allows exit of the FNA needle or any other accessory used parallel to the longitudinal axis of the scope. Preliminary experiences with this scope have reported potential advantages over the conventional linear scope (CLA-EUS) for pseudocysts drainage and for hilar biliary strictures. Moreover, a large experience still unpublished from the Catholic University, Rome, Italy in the use of the FV-EUS for FNA of solid and cystic lesions throughout the GI tract has shown the FV-EUS to be highly effective with a performance that seems at least comparable to that of the CLA-EUS. To date, however, no data comparing the performance of both scopes for FNA of target lesions are available to better clarify the advantages and disadvantages of one scope over the other. We designed a randomized comparative trial in which patients will be randomized to undergo examination with CLA-EUS or with FV-EUS. In case of failure of: (i) visualization of the presumed lesion; (ii) failure in performing the FNA with the scope used based on randomization, a second attempt will be made using the other scope.
Interventions
DEVICEEUS-guided fine needle aspiration
Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
Sponsors
University of Amsterdam
Erasme University Hospital
Catholic University of the Sacred Heart
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Presence of a solid lesion in the GI tract or in one of the adjacent organs identified at abdominal US, CT, MRI/MRCP that needs to be samples with EUS-FNA because unresectable or because tissue characterization is needed to decide further treatment modalities 2. Age greater than 18. 3. Absence of histological or cytological confirmation of malignancy. 4. Informed consent obtained.
Exclusion criteria
1. Patients with active coagulopathy that cannot be corrected after administration of plasma. 2. Resectable lesions that does not need tissue characterization to decide treatment modalities. 3. Pregnancy. 4. Patients who cannot give inform consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Technical performance of the CLA-EUS versus FV-EUS for EUS-FNA | 6 months | (i)Successful lesion identification. (ii)Successful execution of EUS-FNA proved by EUS image confirming the needle into the lesion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic performance of the CLA-EUS versus FV-EUS for EUS-FNA | 6 months | sensitivity, specificity, and diagnostic accuracy of EUS-FNA performed with the two different EUS scopes in the evaluation of solid lesions will be determined and compared |
| Ease of procedure | 6 months | Ease of the procedure will be graded on a analog 5 point score as listed in the table below. Physician will be asked to answer the following questions: * Ease of visualization? * Ease of puncturing? * Ease of moving back and forth inside the lesion? * Ease of overall procedure? |
| Rate of complications | 1 month | Rate of bleeding, pancreatitis, infection and perforation for each procedure will be measured by observation of the patient in the recovery area soonafter and one hour after completion of the procedure. The rate of pancreatitis and infection rate will be also assessed at 24 hours by visiting or calling the patients if discharged |
Countries
Belgium, Italy, Netherlands
Outcome results
None listed